Biotech Startups

SwabBot manufactures automated robotic swabbing devices (SWAB-E and SWAB-B) for cleaning validation in life sciences manufacturing, reducing confined space entry risks and improving consistency in pharmaceutical and biotech facility validation testing.

1 investor

SWAN Genomics is developing a DNA sequencing platform based on plasmonic nanoantenna technology that detects single molecules on native genetic material without amplification, preserving epigenetic information like methylation in a single run. Its in-development Gen 1 platform combines an instrument, reagents, and flowcell aimed at applications spanning clinical diagnostics and genomics research.

1 investor

Swan Neck Bio produces DIRINOC, a ready-to-use, quality-certified starter culture (inoculum) developed from a client's own microbial strain for use in fermentation and biomanufacturing. It applies single-use bioreactor (FlexCell) technology and an AI-assisted development program to create stable, concentrated seed cultures of yeasts, filamentous fungi, and other microbes for biomanufacturers.

1 investor

Swarm Oncology develops personalised T cell therapies for cancer and viral vaccines, using a platform combined with in vivo priming to create targeted, phenotypically optimized treatments based on each patient's tumour biology. The company operates in the cell therapy and biotech space.

1 investor

Exit: Acquired by Integrated DNA Technologies, March 2021.

1 investor

Swift Innovations develops science-backed personal-care and cosmetic products, taking formulations from research and lab stages through to market. It focuses on high-performance skincare and cosmetic solutions with an emphasis on safety, efficacy, and sustainable innovation for global markets.

1 investor

Digital therapeutics developer behind Stanza, an FDA-authorized smartphone behavioral therapy for fibromyalgia symptoms.

1 investor

Swiss Rockets Group is an umbrella company that incubates and accelerates a portfolio of biotech startups working from late-stage pre-clinical through clinical development. It focuses on developing medicines to treat cancer, infectious diseases, and autoimmune disorders.

1 investor

Swiss Decode develops portable DNA detection devices that deliver results in under an hour, enabling evidence collection at the point of need without external laboratory testing.

1 investor

SYFOVRE is a prescription treatment shown to slow the progression of geographic atrophy (GA), the advanced form of dry age-related macular degeneration that affects the retina. It is administered via periodic doses (once every 25-60 days) as determined by a physician.

1 investor

Sygen Pharmaceuticals is a life sciences company that manufactures medicines across more than 16 product categories in ISO- and NAFDAC-approved facilities. Established in 2019 and built on the acquired assets of Nigerian German Chemicals PLC, it focuses on the West African region.

1 investor

Biotechnology company developing therapeutics that target the extracellular matrix in acute and chronic diseases.

1 investor

SymPhysis Medical develops medical devices to treat malignant pleural effusion, a complication affecting late-stage cancer patients. The company's technology, releaze™, is a drainage device designed to improve patient independence and quality of life.

1 investor

Synartro is a clinical-stage Swedish life science company developing intra-articular injection treatments that chemically bind proven drugs to a patented hyaluronan-based local injection technology for sustained drug release without systemic side effects. Its lead candidate SYN321, a slow-release diclofenac injection, is in development as a second-line treatment for symptomatic knee osteoarthritis.

1 investor

SynCardia manufactures the world's first commercially approved total artificial heart for patients with end-stage heart failure awaiting transplant. The company develops and delivers mechanical circulatory support devices as alternatives to heart transplantation for critically ill patients.

1 investor

Synergia Biotech is a clean technology company that produces phycocyanin, a natural blue pigment derived from cyanobacteria grown in Canada using an energy-efficient bioprocess. The pigment serves as a plant-based alternative to synthetic blue colourants for the food and beverage, health and wellness, and personal care industries.

1 investor

Synergic Biosolutions makes a food supplement of calcium ions microencapsulated in prebiotic dietary fiber and enriched with vitamin D. The product is designed for higher absorption and bioavailability, using a smaller amount of pure mineral calcium.

1 investor

Synergio develops natural plant-based bioactive ingredients for healthier and more sustainable consumer products, using a computational platform that identifies plant synergies. It applies data-driven, chemistry-based predictive modeling to create ingredients for health and environmental applications.

1 investor

1 investor

Synmedchem provides synthetic chemistry and medicinal chemistry services for drug discovery and compound design, serving pharmaceutical and biotech clients globally with teams across Australia, China, North America, the UK, and Europe.

1 investor

SynMetabio is a synthetic biology company that develops biomaterials, including mycelium-based leather alternatives, by cultivating fungi on agricultural byproducts such as corn cobs, straw, coffee grounds, distiller's lees, and oil. It operates in the sustainable materials and biotechnology sector.

1 investor

Synokem is a pharmaceutical contract manufacturing and supply company offering branded and institutional medical products through its own manufacturing, quality, and distribution capabilities.

1 investor

Synolo Therapeutics develops conditionally-active immunotherapies for treating cancer, using a proprietary discovery platform to build a pipeline of oncology drug candidates. It aims to offer treatments that are more effective and safer than the current standard of care.

1 investor

Synth-Med develops a drug delivery platform that uses red blood cells to encapsulate therapeutic payloads in nanoparticles and target hard-to-reach tissues, with a lead program delivering a memory-enhancing molecule to the brain for Alzheimer's and other neurodegenerative diseases. The company operates in the biotech and therapeutics sector.

1 investor